NeOnc Technologies CEO Amir Heshmatpour purchased 150,000 shares recently, showing confidence as the company prepares for a key FDA meeting in January 2027. The meeting will discuss accelerated approval and a Phase 3 trial for NEO100, a treatment for aggressive brain cancer. Upcoming scientific presentations and FDA talks on two drug programs provide multiple catalysts for investors. CEO's continued buying and positive Phase 2a results highlight potential growth ahead.
NeOnc Technologies CEO's recent share purchase provides context for readers following health-sector stocks. As of Nov 12, 2026 22:11 WIB, out of 150 priced health-sector US stocks tradable on Pluang, 42 rose and 108 fell. Notable movers include AXGN at USD 54.92 with a 1-day change of -6.33%, NVAX at USD 9.36 down 6.26%, and RXRX at USD 3.37 down 6.13%, with RXRX showing 100% buy order activity on Pluang.
TRM Labs introduced the Disruption Awards to recognize coalitions of public and private organizations that successfully disrupted major cybercrimes in 2026. Winners include groups that took down a phishing service responsible for most Microsoft-block...
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
atQor has been named a finalist for the 2026 Microsoft Partner of the Year Award in the Agents category, recognized for its innovative and scalable agentic AI solutions deployed across nine industries. The company developed 252 AI agents in FY26, wit...
